Mode
Text Size
Log in / Sign up

Expert review outlines diagnostic and therapeutic management strategies for eosinophilic granulomatosis with polyangiitis.

Expert review outlines diagnostic and therapeutic management strategies for eosinophilic granulomato…
Photo by iMattSmart / Unsplash
Key Takeaway
Consider expert review strategies to support structured care for EGPA patients.

This publication is an expert review and perspective piece addressing the diagnostic and therapeutic management strategies for patients with eosinophilic granulomatosis with polyangiitis (EGPA). The scope encompasses the use of glucocorticoids, immunosuppressants, and anti–IL-5/IL-5R biologics within the context of clinical practice. Because this is a narrative review rather than a randomized trial or cohort study, no specific sample size or numerical efficacy results are provided in the source material.

The primary objective of this review is to support real-world decision-making and facilitate a more consistent and structured approach to care for this condition. Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, are not reported in this specific perspective. Consequently, the text does not provide quantitative evidence regarding the frequency or severity of treatment-related harms.

Key limitations of this evidence include the absence of a defined comparator group, the lack of reported primary or secondary outcomes, and the inherent constraints of an expert opinion rather than empirical data. No specific limitations were listed in the source text, and funding or conflicts of interest were not reported. The review does not establish causality between interventions and outcomes due to its observational nature.

Clinicians should interpret these management strategies as a framework for structured care rather than evidence-based recommendations derived from controlled trials. The absence of numerical data means that practice relevance is based on expert consensus regarding the utility of these strategies in facilitating consistency, rather than on statistical significance or effect sizes.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and heterogeneous immune-mediated disorder in which eosinophilic inflammation, vasculitis, and airway disease coexist in highly variable combinations. In clinical practice, diagnosis remains challenging because no single biomarker reliably captures disease complexity, and therapeutic decisions must still be based on careful integration of clinical, laboratory, imaging, and histopathological findings. In recent years, EGPA management has evolved from a largely glucocorticoid-based approach toward a more phenotype-oriented strategy that distinguishes eosinophilic and vasculitic manifestations and incorporates targeted biologic therapies. This Perspective discusses current challenges and emerging opportunities in EGPA diagnosis and treatment, with emphasis on early recognition, multidisciplinary assessment, glucocorticoid-sparing strategies, and individualized long-term follow-up. Specific recommendations are provided on diagnostic orientation, phenotype-driven therapeutic selection, and the practical use of conventional immunosuppressants and anti–IL-5/IL-5R biologics according to disease severity and organ involvement. In addition, we propose a new treatment algorithm intended to support real-world decision-making and to facilitate a more consistent and structured approach to care. By combining expert recommendations with a forward-looking perspective on evolving therapeutic strategies, this article aims to contribute to safer, more effective, and more personalized management of patients with EGPA.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.